Biomedical testing company Beckman Coulter (Fullerton, CA) has agreed to acquire Biosite (San Diego, CA), an immunoassay company focused on point-of-care testing (also called near-patient testing). Acquiring Biosite would enable Beckman to gain a strong foothold in the near-patient testing market, both inside and outside of hospitals. Valued at $1.55 billion, with an offer price of $85 per share in cash, the transaction is expected to close within the next 40 to 60 days.

Subscribers: click here for the full story

Non-Subscribers: click here to subscribe

April 2007 - Table of Contents

LIR April 2007 (full PDF issue)

Financial Benchmarks at 10 Major Labs: Quest and LabCorp See Gains in Revenue and Profit Per Billable Test

Aetna’s Lab Is Quest, LabCorp Takes a Hit

Kennedy to Fast Track New Bill to Regulate Lab Tests

Decatur Memorial Hospital Laboratory Enters the Molecular World

Benchmarking the Major Labs

Genova Diagnostics Buys Texas Reference Lab

Beckman Coulter to Buy Biosite for $1.55 billion

CMS Continues Rolling Out Medically Unlikely Edits

MDS Completes $615M Purchase of Molecular Devices

Lab Stocks Rise 3% Led by Orchid and Clarient

Biggest Challenges for AP Practices